These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 17805201)
1. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201 [TBL] [Abstract][Full Text] [Related]
2. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912 [TBL] [Abstract][Full Text] [Related]
3. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Fride E; Ginzburg Y; Breuer A; Bisogno T; Di Marzo V; Mechoulam R Eur J Pharmacol; 2001 May; 419(2-3):207-14. PubMed ID: 11426843 [TBL] [Abstract][Full Text] [Related]
4. Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. Avraham Y; Menachem AB; Okun A; Zlotarav O; Abel N; Mechoulam R; Berry EM Brain Res Bull; 2005 Mar; 65(2):117-23. PubMed ID: 15763177 [TBL] [Abstract][Full Text] [Related]
5. Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters. Ho JM; Smith NS; Adams SA; Bradshaw HB; Demas GE J Neuroendocrinol; 2012 Jul; 24(7):1030-9. PubMed ID: 22420341 [TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748 [TBL] [Abstract][Full Text] [Related]
7. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354 [TBL] [Abstract][Full Text] [Related]
8. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909 [TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Després JP Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB Chen W; Liu H; Guan H; Xue N; Wang L Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874 [TBL] [Abstract][Full Text] [Related]
11. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734 [TBL] [Abstract][Full Text] [Related]
12. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510 [TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374 [TBL] [Abstract][Full Text] [Related]
14. Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. Tallett AJ; Blundell JE; Rodgers JR Behav Pharmacol; 2007 Nov; 18(7):591-600. PubMed ID: 17912043 [TBL] [Abstract][Full Text] [Related]
15. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056 [TBL] [Abstract][Full Text] [Related]
16. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770 [TBL] [Abstract][Full Text] [Related]
17. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Forget B; Barthélémy S; Saurini F; Hamon M; Thiébot MH Psychopharmacology (Berl); 2006 Nov; 189(1):59-69. PubMed ID: 16969683 [TBL] [Abstract][Full Text] [Related]
18. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Gamble-George JC; Conger JR; Hartley ND; Gupta P; Sumislawski JJ; Patel S Psychopharmacology (Berl); 2013 Aug; 228(3):401-9. PubMed ID: 23483200 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. Mukhopadhyay P; Bátkai S; Rajesh M; Czifra N; Harvey-White J; Haskó G; Zsengeller Z; Gerard NP; Liaudet L; Kunos G; Pacher P J Am Coll Cardiol; 2007 Aug; 50(6):528-36. PubMed ID: 17678736 [TBL] [Abstract][Full Text] [Related]